<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Congenital pulmonary airway malformation: Prenatal diagnosis and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Congenital pulmonary airway malformation: Prenatal diagnosis and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Congenital pulmonary airway malformation: Prenatal diagnosis and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alexia Egloff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dorothy I Bulas, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah Levine, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Louise Wilkins-Haug, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H5018929"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Congenital lung masses include congenital pulmonary airway malformation (CPAM, previously known as congenital cystic adenomatoid malformation [CCAM]), bronchopulmonary sequestration (BPS, also called lung or pulmonary sequestration), congenital lobar overinflation, bronchogenic cyst, and bronchial atresia. Hybrid lesions are common, which suggests that these masses represent a spectrum of abnormalities  (<a class="graphic graphic_figure graphicRef130725" href="/d/graphic/130725.html" rel="external">figure 1</a>). The abnormalities in this spectrum are characterized by abnormal development of the pulmonary airways, parenchyma, and/or vasculature, likely secondary to obstruction. The level, degree, and timing of obstruction determine the resulting pathology [<a href="#rid1">1-3</a>]. </p><p>The prenatal course of CPAM depends on the size of the mass, amount of mediastinal shift, fetal hemodynamics, and associated anomalies. In the absence of hydrops, the prognosis is good, with reported live birth rates ≥95 percent. </p><p>Several interventions have been developed for managing hydropic fetuses remote from term, with the goal of improving fetal hemodynamics, preventing lung hypoplasia, and improving survival. </p><p>Postnatally, surgical excision in the neonatal period is curative and the prognosis for survival is excellent. In the absence of surgery, the most common postnatal complication of CPAM is recurrent pulmonary infection; there is also a weak association with malignancy.</p><p>This topic will focus on prenatal diagnosis and management of CPAM. Prenatal diagnosis and management of BPS and hybrid BPS/CPAM lesions are reviewed separately (see  <a class="medical medical_review" href="/d/html/13515.html" rel="external">"Bronchopulmonary sequestration: Prenatal diagnosis and management"</a>). Postnatal management and outcome of CPAM are also reviewed separately. (See  <a class="medical medical_review" href="/d/html/6346.html" rel="external">"Congenital pulmonary airway malformation"</a>.)</p><p class="headingAnchor" id="H3981324331"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Congenital pulmonary airway malformation (CPAM) is one of the most common lung lesions diagnosed prenatally (59 percent of prenatal lung lesions [<a href="#rid4">4</a>]), although the birth prevalence is quite low, between 0.87 and 1.92/10,000 live births [<a href="#rid5">5</a>]. It is usually sporadic and isolated and has no familial recurrence [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/6346.html" rel="external">"Congenital pulmonary airway malformation", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H567774992"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Prenatally, CPAM is classified as microcystic (74 percent) or macrocystic (26 percent) [<a href="#rid4">4</a>] based on imaging characteristics [<a href="#rid6">6</a>]. Prenatal percentages are different from postnatal percentages, probably because macrocystic lesions are more likely to be symptomatic postnatally, resulting in a higher reported incidence of macrocystic lesions in postnatal series [<a href="#rid4">4</a>].</p><p>Stocker's more refined classification system is useful prognostically, but not practical prenatally since tissue is not available for histologic analysis [<a href="#rid7">7</a>]. There are five subtypes of malformations (0-tracheobronchial, 1-bronchial, 2-bronchiolar, 3-alveolar duct, 4-acinar) based on cyst size and histopathology; immunohistochemistry and proteomics suggest they occur at different stages of lung development [<a href="#rid5">5</a>]. A brief synopsis of characteristics of the five types is available in the table  (<a class="graphic graphic_table graphicRef130813" href="/d/graphic/130813.html" rel="external">table 1</a>) and described in more detail separately. (See  <a class="medical medical_review" href="/d/html/6346.html" rel="external">"Congenital pulmonary airway malformation", section on 'Pathology'</a>.)</p><p class="headingAnchor" id="H5019266"><span class="h1">PRENATAL DIAGNOSIS</span></p><p class="headingAnchor" id="H1507021604"><span class="h2">Imaging modality</span><span class="headingEndMark"> — </span>Ultrasound is the primary modality for imaging the fetal chest and detecting fetal chest masses [<a href="#rid8">8</a>]. However, sonographic assessment of lung parenchyma can be limited due to maternal obesity, oligohydramnios, overlying ribs, and fetal lie. Magnetic resonance imaging (MRI) is less limited by these factors, thus MRI can be a useful adjunct for confirming the presence of a mass, further characterizing normal and abnormal anatomy, and assessing residual lung volume, which is useful for counseling and obstetric management [<a href="#rid9">9-13</a>]. (See <a class="local">'Role of magnetic resonance imaging'</a> below.)</p><p class="headingAnchor" id="H2055889271"><span class="h2">Appearance of normal lung</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ultrasound images</strong> – On axial images, the normal fetal chest is oval or round, with the heart in the anterior half of the left chest and bordered by lung parenchyma  (<a class="graphic graphic_diagnosticimage graphicRef63320" href="/d/graphic/63320.html" rel="external">image 1</a>). Inferiorly, the diaphragms are dome-shaped and hypoechoic. Lung parenchyma appears homogeneous and slightly hyperechogenic compared with the fetal liver, and its echogenicity increases with gestational age [<a href="#rid14">14</a>]. The fetal airway is not well delineated on ultrasound.</p><p></p><p class="bulletIndent1">Fetal lung volume increases with gestational age with the right lung typically measuring 56 percent of total lung volume. Three-dimensional and four-dimensional ultrasound imaging appear to be more useful than two-dimensional ultrasound for estimating lung volume [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Magnetic resonance images</strong> – On MRI, the normal fetal lung has a homogeneously moderate high signal on T2-weighted (T2w) chest  (<a class="graphic graphic_diagnosticimage graphicRef74495" href="/d/graphic/74495.html" rel="external">image 2</a>) [<a href="#rid14">14</a>]. The T2 signal increases with gestational age as increasing numbers of alveoli and production of alveolar fluid develop and decreases in signal with T1-weighted (T1w) [<a href="#rid16">16</a>]. When normal lung is compressed by either a lung mass or an extraparenchymal lesion, it appears slightly hypointense compared with noncompressed normal lung [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">The liver, mediastinal structures, and lung parenchyma are easily differentiated by MRI. Compared with adjacent lung, the liver has a lower signal on T2w and higher signal on T1w. The fetal airway can be seen well due to fluid within the larynx, trachea, and bronchi. The thymus is homogeneous and has a higher signal than the heart, which appears as a dark flow void on single slice fast spin echo sequences (SSPSE) and high signal on steady state free precession sequences (SSFP).</p><p></p><p class="headingAnchor" id="H15360242"><span class="h2">CPAM</span></p><p class="headingAnchor" id="H2693562371"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>The prenatal diagnosis of CPAM is most commonly based on ultrasound findings first detected in the second trimester. It can be classified as macrocystic, microcystic, or mixed [<a href="#rid4">4</a>] based on the ultrasound appearance [<a href="#rid6">6</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Macrocystic CPAM is characterized by anechoic cysts &gt;5 mm in diameter, often surrounded by hyperechogenic lung parenchyma  (<a class="graphic graphic_diagnosticimage graphicRef64147" href="/d/graphic/64147.html" rel="external">image 3</a>) (type I), which is bright on T2w MRI due to the large amount of fluid within the lesion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Microcystic CPAM is characterized by a solid-appearing homogeneous mass that is hyperechogenic compared with adjacent normal lung parenchyma, and composed of microcystic lesions &lt;5 mm in diameter  (<a class="graphic graphic_diagnosticimage graphicRef77848" href="/d/graphic/77848.html" rel="external">image 4</a>) (type III). As gestational age increases, microcystic lesions become more difficult to visualize due to increased echogenicity of surrounding normal lung [<a href="#rid16">16</a>]. Shadowing from overlying ribs also makes assessment of the mass more difficult in the third trimester. Microcysts also are characteristically T2 bright on MRI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mixed CPAM lesions contain both solid and cystic components  (<a class="graphic graphic_diagnosticimage graphicRef71008" href="/d/graphic/71008.html" rel="external">image 5</a>) (type II).</p><p></p><p>On color and power Doppler, the arterial supply and venous drainage are from the pulmonary circulation. If a systemic feeding vessel is noted, the lesion is considered a bronchopulmonary sequestration (BPS) if it is solid and a hybrid BPS/CPAM lesion if it is both cystic and solid. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>There have been a few cases of CPAM with decreased echogenicity/T2w hypointense signal [<a href="#rid17">17</a>], which can be related to immature parenchymal development and increased mesenchymal tissue or CPAM regression. (See <a class="local">'Role of magnetic resonance imaging'</a> below.)</p><p>Additional findings include:</p><p class="bulletIndent1"><span class="glyph">●</span>CPAM can have a connection to the tracheobronchial tree. Bronchial atresia has been noted pathologically in up to 70 percent of cases [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CPAMs develop in the right and left lungs with equal frequency [<a href="#rid19">19</a>]; bilateral lung involvement is rare [<a href="#rid20">20</a>]. Only one lobe is involved in 85 to 95 percent of cases and the lower lobe is the most common site, but any lobe can be affected [<a href="#rid6">6,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Large or rapidly growing lesions can cause mediastinal shift to the contralateral side, possibly with cardiac rotation. Particular attention should be paid to mediastinal shift since a severe shift resulting in compression of the inferior vena cava (IVC) and heart can lead to hydrops  (<a class="graphic graphic_diagnosticimage graphicRef63018" href="/d/graphic/63018.html" rel="external">image 6</a>). (See <a class="local">'Hydrops with abnormal fetal echocardiography'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The esophagus can become compressed and obstructed, resulting in proximal dilation, a small stomach, and polyhydramnios. The ipsilateral diaphragm may be flattened.</p><p></p><p class="headingAnchor" id="H2583252208"><span class="h3">Postdiagnostic imaging evaluation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment for associated anomalies</strong> – Because 10 to 20 percent of fetuses with CPAM have associated congenital abnormalities, a comprehensive fetal survey should be performed. The most common associated anomalies are cardiovascular and urogenital, but others have been described, including tracheoesophageal fistula, cleft lip and palate, and diaphragmatic, central nervous system, bony, and other pulmonary abnormalities [<a href="#rid22">22-25</a>]. (See  <a class="medical medical_review" href="/d/html/6346.html" rel="external">"Congenital pulmonary airway malformation", section on 'Neonatal period'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetal echocardiography</strong> is recommended initially to rule out congenital cardiac anomalies [<a href="#rid26">26</a>]. It is also performed to assess cardiac function in cases with, or at high risk for, hydrops [<a href="#rid27">27</a>]. Echocardiographic assessment includes the size of heart chambers, evaluation for valvar regurgitation, measurement of contractility and ventricular function, and Doppler examination of the IVC, ductus venosus, and umbilical vein [<a href="#rid27">27</a>]. A cardiovascular profile score can help plan management and predict outcome [<a href="#rid27">27,28</a>]; this point system score takes into account hydrops, heart size, cardiac function, and findings on Doppler velocimetry of the ductus venosus, umbilical vein, and umbilical artery. (See <a class="local">'Poor prognostic factors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quantitative measurements </strong>– Quantitative evaluation helps predict the prenatal and postnatal course of the disease. The following prenatal ultrasound measurements have been described. Their significance as prognostic factors is discussed below. (See <a class="local">'Quantitative measurements'</a> below.)</p><p></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CPAM volume ratio (CVR)</strong> – Obtained by calculating the volume of the lung mass using the formula for the volume of a prolate ellipse (0.52 x each of three orthogonal measurements) and normalizing it by gestational age. To normalize by gestational age, the lung mass volume should be divided by the head circumference [<a href="#rid29">29</a>]:</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent3">CVR = height x anteroposterior diameter x transverse diameter x 0.52 (constant)/head circumference.</p></div></div><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mass-to-thorax ratio (MTR)</strong> – The ratio between the transverse diameter of the mass and the transverse diameter of the thorax. It is measured on an axial image of the chest, where the four-chamber view of the heart is present.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lesion to lung volume ratio (LLV)</strong> – The sum of all measurements of the mass is multiplied by the section thickness to obtain a volume in cubic centimeters and is divided by the observed normal total fetal lung volume (TFLV), which is the volume of normal lung excluding the volume of the lung mass.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Observed/expected normal fetal lung volume (O/E-NFLV)</strong> – The observed lung volume is the sum of all measurements of the fetal lung excluding the lung mass multiplied by the section thickness to obtain a volume in cubic centimeters. This is then divided by the mean expected TFLV for the gestational age.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Observed to expected lung area-to-head circumference ratio (observed/expected LHR)</strong> – This ratio is used to predict outcomes of fetuses with congenital diaphragmatic hernia, and its use has been assessed in the evaluation of fetuses with CPAM, though with less sensitivity [<a href="#rid30">30</a>]. It is described in detail separately. (See  <a class="medical medical_review" href="/d/html/6800.html" rel="external">"Congenital diaphragmatic hernia: Prenatal issues", section on 'Lung area to head circumference ratio'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiomediastinal shift angle (CMSA)</strong> – A transverse image of the fetal chest with the four chamber view of the heart is obtained and a reference line is drawn from the center of the vertebral body to the sternum [<a href="#rid31">31</a>]. Normally, this line lies at a 45-degree angle to the interventricular septum and intersects the atrial septum. When this does not occur because of mediastinal shift, a second index line is drawn from the center of the vertebral body to cross through the displaced atrial septum and on to the chest. The angle between the reference and index lines is the CMSA.</p><p></p><p class="headingAnchor" id="H2413418768"><span class="h3">Role of magnetic resonance imaging</span><span class="headingEndMark"> — </span>MRI is a useful adjunct for supporting the diagnosis and increasing specificity [<a href="#rid9">9,21,32</a>]. It can be used to confirm the presence and size of the mass, particularly when it is difficult to see by ultrasound because the mass involves the entire lung or hydrops or bilateral lesions are present [<a href="#rid14">14,33</a>]. It can also be used to measure lung volume and detect associated fetal abnormalities. This additional information can be useful for counselling, determining frequency of follow-up examinations, and preparation for delivery and perinatal care. (See <a class="local">'Poor prognostic factors'</a> below.)</p><p>The fetal MRI-derived volume ratio (LMVR) is analogous to the ultrasound-derived CVR. The volume in cubic centimeters is obtained by multiplying the sum of all measurements of the mass by the section thickness. The volume is then divided by the head circumference in centimeters to derive the LMVR.</p><p>The optimal timing of fetal MRI to assess suspected CPAM is unclear. In the late third trimester, the T2w signal of normal lung increases, which may diminish differentiation between a type III CPAM and normal parenchyma. As on ultrasound, the lung lesion on MRI may demonstrate a macrocystic, microcystic, or mixed appearance, which are of high signal on T2w compared with normal lung parenchyma. Careful assessments of vascularity and whether the T2w signal is high or low can help in the differential diagnosis. Normal pulmonary vascularity coursing through a mass suggests congenital lobar overinflation, while a feeding vessel from the aorta is consistent with a BPS or hybrid lesion. Rarely, a CPAM can be low signal on T2w and hypoechoic on ultrasound [<a href="#rid17">17</a>]. These CPAMs have a more immature parenchymal development with increased mesenchymal tissue, similar to myofibroblastic tumors, or may be resolving CPAMs as the lesion decreases in size and collapses. Polyhydramnios is often associated with these unusual, low-signal, hypoechoic lesions. </p><p class="bulletIndent1">In one series in which two fetal MRIs were performed early (20 to 26 weeks of gestation) and late (&gt;32 weeks of gestation), the type of malformation was concordant with postnatal diagnosis in 19 of 26 cases (73 percent) with early MRI versus 22 of 26 cases (85 percent) with late MRI [<a href="#rid34">34</a>]. The authors suggested that the addition of a later MRI may improve clinical management and could delay or reduce postnatal imaging.</p><p></p><p class="headingAnchor" id="H5019524"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The prenatal differential diagnosis of CPAM includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchopulmonary sequestration (BPS) </strong>– BPS is a homogeneous echogenic mass of the lung parenchyma with well-defined borders, most frequently left-sided but bilateral cases have been described [<a href="#rid35">35</a>]. In contrast to CPAM, BPS does not communicate with the tracheobronchial tree. Another difference from CPAM is that BPS has anomalous systemic feeding and draining vessels that can often be identified by color and power Doppler imaging, whereas blood flow to CPAM is through the normal pulmonary vasculature [<a href="#rid12">12,36</a>]. </p><p></p><p class="bulletIndent1">Hybrid lesions containing features of both CPAM and BPS are the second most common lung lesion (38 percent) [<a href="#rid4">4</a>] and, by imaging, contain mixed cystic and solid components with anomalous feeding systemic vessels. These lesions have a better prognosis than CPAM alone. (See  <a class="medical medical_review" href="/d/html/13515.html" rel="external">"Bronchopulmonary sequestration: Prenatal diagnosis and management"</a> and  <a class="medical medical_review" href="/d/html/6341.html" rel="external">"Bronchopulmonary sequestration"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital lobar overinflation (CLO)/congenital lobar emphysema (CLE)/bronchial atresia</strong> – Criteria for CLO/CLE/bronchial atresia include hyperlucent lung postnatally, normal lung architecture, and absence of macroscopic cysts. CLO/CLE/bronchial atresia may involve one or more lobes or segments of one or both lungs [<a href="#rid37">37</a>]. Prenatally, the diagnosis can be difficult to differentiate from microcystic CPAM and BPS. The presence of normal pulmonary vascularity excludes BPS and the lack of cysts excludes CPAM. Diagnosis is confirmed by postnatal computed tomography with intravenous contrast [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/6350.html" rel="external">"Congenital lobar emphysema"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchogenic cyst</strong> –<strong> </strong>Bronchogenic macrocysts arise from abnormal budding of the ventral foregut along the tracheobronchial tree. The thin-walled cystic lesions are covered by respiratory epithelium [<a href="#rid38">38</a>]. They are typically isolated lesions located in the cervical, paratracheal, subcarinal, hilar or mediastinal area, or within the region of the carina, and surrounded by normal lung parenchyma [<a href="#rid39">39,40</a>]. The diagnosis should be suspected when an isolated macrocyst appears to arise from the wall of the trachea or proximal airways [<a href="#rid40">40</a>]. Fifteen percent of cases are intraparenchymal rather than adjacent to the tracheobronchial tree. In these cases, it may be difficult to differentiate a bronchogenic cyst from a macrocystic CPAM prenatally. (See  <a class="medical medical_review" href="/d/html/6377.html" rel="external">"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula", section on 'Bronchogenic cyst'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diaphragmatic hernia</strong> –<strong> </strong>Herniated bowel loops in the hemithorax can mimic a multicystic, heterogeneous lung mass. Mediastinal and cardiac deviation may be the only hint that a congenital diaphragmatic hernia is present in cases when the stomach remains infradiaphragmatic. When the stomach is herniated into the hemithorax, nonvisualization of fluid-filled stomach (stomach bubble) within the abdomen is helpful for making the diagnosis [<a href="#rid21">21,36</a>]. Peristalsis of bowel loops in the thorax can sometimes be seen by ultrasound [<a href="#rid21">21</a>]. Deviation of the umbilical portion of the portal vein suggests liver herniation into the thorax. In subtle and uncertain cases, use of the umbilical vein ratio can help in the ultrasound diagnosis since almost all congenital diaphragmatic hernias have an abnormal ratio [<a href="#rid41">41</a>]. </p><p></p><p class="bulletIndent1">Magnetic resonance imaging (MRI) is particularly useful in assessing the amount of liver herniation and delineation of meconium filled small and large bowel in the chest. Meconium is dark on T2 and bright on T1, while liver is higher signal on T1-weighted (T1w) and intermediate signal on T2-weighted (T2w), and thus easily differentiated from adjacent lung. (See  <a class="medical medical_review" href="/d/html/6800.html" rel="external">"Congenital diaphragmatic hernia: Prenatal issues"</a> and  <a class="medical medical_review" href="/d/html/4963.html" rel="external">"Congenital diaphragmatic hernia in the neonate"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital high airway obstruction (CHAOS)</strong> –<strong> </strong>CHAOS secondary to laryngeal or tracheal atresia should be included in the differential diagnosis when the diagnosis of bilateral large CPAMs is being considered [<a href="#rid14">14,36</a>]. Aberrant pulmonary budding off the foregut is present in CHAOS and most CHAOS lesions also have a connection with the esophagus. Both lungs appear symmetrically enlarged and echogenic by ultrasound due to fluid trapping. The diaphragms are flattened and everted. Compression of the heart and great vessels may result in heart failure and hydrops [<a href="#rid42">42</a>]. Compression of the esophagus may lead to polyhydramnios. </p><p></p><p class="bulletIndent1">MRI demonstrates abnormally large high signal lungs on T2w images. Identification of dilated fluid-filled trachea and bronchi confirms the diagnosis. When suspected, a thorough examination should be performed and genetic testing offered to look for other congenital structural and chromosomal abnormalities as CHAOS can be associated with trisomy 9, trisomy 16, and chromosome 5p deletion [<a href="#rid43">43</a>]. Prognosis is poor [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurenteric/enteric cysts</strong> –<strong> </strong>These cysts are formed by failure of the gastrointestinal track to separate from the primitive neural crest. Neurenteric cysts are typically associated with vertebral anomalies and are located in the posterior mediastinum. Enteric or duplication cysts are seen in adjacent to bowel and have no communication with the neural track.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mediastinal cystic teratoma</strong> –<strong> </strong>These tumors can be cystic and/or solid and are located in the anterior mediastinum. They have increased vascularity, which can be noted on Doppler imaging [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rare fetal pulmonary neoplasms </strong>– Rare neoplasms, such as the pleuropulmonary blastoma (PPB), congenital peribronchial myofibroblastic tumor, and the fetal lung interstitial tumor (FLIT), should also be considered in differential diagnosis. These tumors can be cystic and/or solid and mimic a CPAM. While the majority of these tumors are discovered postnatally, prenatal diagnoses have been reported [<a href="#rid45">45-48</a>].</p><p></p><p class="bulletIndent1">CPAM and PPB can be difficult to differentiate by imaging. In a systematic review, a lesion identified as CPAM by imaging was actually a PPB in 4 percent of cases [<a href="#rid49">49</a>]. There was no evidence to suggest that a CPAM evolves into a PPB. The presence of pleural effusions raises the chances of PPB since effusions are more commonly associated with PPB than with CPAM [<a href="#rid50">50</a>]. A germline mutation in the<em> DICER1</em> gene [<a href="#rid51">51</a>] has been found in two-thirds of PPB cases [<a href="#rid52">52</a>]. The identification of this germ-line mutation could also be useful in differential diagnosis when the family history is positive for tumors associated with PPB, such as thyroid cancer [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1">Presentation later in gestation in combination with a solid appearance with radiating curved bands of high signal within and along the periphery of the lesion suggest FLIT and might help differentiate CPAM from this tumor [<a href="#rid53">53</a>].</p><p></p><p class="headingAnchor" id="H5019798"><span class="h1">PRENATAL COURSE</span></p><p class="headingAnchor" id="H777073252"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The prenatal course of CPAM depends more on the gestational age, size of the mass, amount of mediastinal shift, fetal hemodynamics, and associated anomalies than on the type of lesion (macrocystic versus microcystic) [<a href="#rid6">6,14,38</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth velocity across gestation</strong> – Longitudinal studies of fetal CPAM have reported that most have rapid progressive growth from approximately weeks 20 to 26 of gestation, peaking at approximately 25 weeks [<a href="#rid29">29,54</a>], and then growth plateaus and often regresses [<a href="#rid55">55</a>]. Macrocystic lesions grow less rapidly than microcystic/solid lesions. CPAM growth at 20 to 26 weeks is often relatively greater than overall fetal growth, increasing the risk for mediastinal shift and development of hydrops during this time. Therefore, CPAM should be followed closely from 20 to 26 weeks, with weekly scans in cases where mediastinal shift is increasing. (See <a class="local">'Follow-up imaging'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regression </strong>– Fifteen percent of the masses decrease in size during the late second and the third trimesters; the majority have a relative decrease in size due to normal fetal thoracic growth, but a few increase in size [<a href="#rid6">6,54</a>]. As the size decreases, echogenicity can become similar to that of surrounding normal lung due to both increase in normal lung echogenicity and decrease in echogenicity of the CPAM. On T2-weighted magnetic resonance imaging (MRI), as the lesions regress, their signal intensity may become less than a normal lung. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prenatal resolution/persistence and postnatal findings</strong> – The mass appears to resolve by ultrasound before delivery in 50 percent of cases [<a href="#rid56">56</a>], usually in cases with a microcystic/solid appearance and a low CPAM volume ratio (CVR) [<a href="#rid57">57</a>]. On postnatal imaging, 60 percent of these cases show no abnormality. When postnatal imaging is normal, CPAM may not have been the underlying cause for the anomaly seen prenatally, instead it may have been a transient bronchial tree obstruction with retention of fluid [<a href="#rid56">56</a>] or a lesion that outgrew its blood supply or underwent spontaneous torsion [<a href="#rid57">57</a>]. The remaining 40 percent show a residual lesion that was no longer recognized prenatally due to the normal increase in lung echogenicity late in pregnancy, which makes differentiating normal from abnormal lungs difficult [<a href="#rid29">29</a>]. Computed tomography or MRI may be needed to demonstrate these residual lesions postnatally.</p><p></p><p class="bulletIndent1">In the 50 percent of cases that do not appear to resolve before delivery, postnatal imaging confirms persistence of the mass in over 95 percent of cases.</p><p></p><p class="headingAnchor" id="H650869301"><span class="h2">Development of hydrops</span><span class="headingEndMark"> — </span>Fetuses with large masses can develop hydrops secondary to impaired venous return due to displacement and compression of the heart, vena cava, or ductus venosus, which can be associated with poor heart function [<a href="#rid4">4,27,58,59</a>]. Hydrops can also be caused by compression of lymphatic structures (cisterna chyli or thoracic duct), which generally is not associated with poor heart function (see <a class="local">'Hydrops with abnormal fetal echocardiography'</a> below). If hydrops has not developed by approximately 28 weeks, it is unlikely to develop since CPAM growth plateaus by the end of the second trimester and the fetal thorax continues to increase [<a href="#rid29">29,55</a>]. Hydrops has not been described after mass growth plateaus.</p><p>An additional complication of fetal hydrops is the association with maternal mirror syndrome (generalized maternal edema, often with pulmonary involvement, that "mirrors" the edema of the hydropic fetus and placenta). (See  <a class="medical medical_review" href="/d/html/6794.html" rel="external">"Nonimmune hydrops fetalis", section on 'Mirror syndrome'</a>.)</p><p class="headingAnchor" id="H4223223108"><span class="h2">Poor prognostic factors</span></p><p class="headingAnchor" id="H2825392187"><span class="h3">Hydrops with abnormal fetal echocardiography</span><span class="headingEndMark"> — </span>Hydrops associated with poor heart function is associated with a high risk for perinatal death, so early intervention should be considered [<a href="#rid27">27</a>]. When hydrops is not associated with poor heart function, its presence is not a direct predictor of demise; live birth rates are ≥95 percent without intervention [<a href="#rid30">30,32,56,59-61</a>]. Cases of spontaneous resolution of early hydrops (pleural effusion and/or ascites) without intervention have been reported, but these cases are extremely rare [<a href="#rid21">21</a>] and tend to be diagnosed around the time when the relative growth of the CPAM plateaus, so that mediastinal shift decreases without iatrogenic intervention.</p><p>In a study including 24 fetuses with lung masses at high risk for hydrops, only 13 percent of hydropic fetuses with an abnormal echocardiogram survived in the absence of fetal surgery [<a href="#rid27">27</a>]. On the other hand, 100 percent of hydropic fetuses with a normal echocardiogram survived. Thus, in an hydropic fetus with a large lung mass, abnormal echocardiography appears to be a good predictor of poor outcome and should be considered an indication for urgent intervention.</p><p class="headingAnchor" id="H3305559923"><span class="h3">Quantitative measurements</span><span class="headingEndMark"> — </span>The initial ultrasound can help predict if the lesion will regress, stabilize, or continue to grow, depending on the gestational age at the time of the examination and severity of mass effect. The use of quantitative measures such as CVR, mass-to-thorax ratio (MTR), lung mass volume ratio (LMVR), lesion to lung volume ratio (LLV), observed to expected normal fetal lung volume ratio (O/E-NFLV), observed to expected lung area-to-head circumference ratio (O/E-LHR), or cardiomediastinal shift angle (CMSA) can aid in risk stratification and help direct perinatal management and counseling [<a href="#rid30">30,59,61</a>]. Measurement of these ratios is described above (See <a class="local">'Postdiagnostic imaging evaluation'</a> above.) and interpretation is discussed below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CVR</strong> – CVR &gt;1.6 is generally considered predictive of risk for hydrops, respiratory distress at birth, and probable need for early surgery [<a href="#rid29">29,61</a>], whereas CVR &lt;0.91 at presentation predicts a favorable outcome, so follow-up prenatal examinations can be less frequent [<a href="#rid30">30</a>]. In a series of 58 fetuses with CPAM, the rate of subsequent development of hydrops for CVR ≤1.6 and &gt;1.6 was 7 out of 42 (17 percent) and 12 out of 16 (75 percent), respectively, and survival was 40 out of 42 (94 percent) versus 9 out of 16 (56 percent) after fetal intervention, respectively [<a href="#rid29">29</a>]. The predictive value of CVR was enhanced by excluding fetuses with CVR ≤1.6 and a dominant cyst because some of these cysts rapidly enlarged from fluid accumulation while solid masses grew more slowly. When only fetuses with CVR ≤1.6 and no dominant cysts were considered, hydrops developed in only 1 out of 36 (2.8 percent).</p><p></p><p class="bulletIndent1">Thresholds lower than &gt;1.6 have also been suggested since they are more predictive of important adverse outcomes other than hydrops [<a href="#rid58">58,62</a>]. For example, a CVR &gt;1.1 is highly predictive of requiring urgent surgical intervention at birth and thus would be an indication for planned delivery at a hospital with personnel and other resources for neonatal stabilization and early surgical intervention [<a href="#rid58">58</a>]. In one retrospective study of fetal lung lesions, a predelivery CVR &gt;1 in nonhydropic fetuses was predictive of respiratory symptoms at birth (sensitivity, specificity, positive and negative predictive values: 75, 98, 75, and 98 percent) and perinatal resection (sensitivity, specificity, positive and negative predictive values: 100, 98, 75, and 100 percent) [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MTR</strong> – MTR &lt;0.51 suggests the fetus is at low risk for developing complications [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LMVR</strong> – In a 10-year retrospective series including 128 fetuses with congenital lung masses, a cutoff of &gt;2 was associated with worse perinatal outcome with 84 percent sensitivity and 99 percent specificity; a value &gt;1.3 was associated with neonatal respiratory distress at delivery (89 versus 7 percent with LMVR &lt;1.3) [<a href="#rid59">59</a>]. LMVR &gt;2 was also associated with hydrops (42 versus 2 percent with LMVR &lt;2) and heart failure (32 versus 2 percent with LMVR &lt;2).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>O/E-NFLV</strong> – O/E-NFLV of &lt;75 percent predicts a worse postnatal course with 57 percent sensitivity and 80 percent specificity [<a href="#rid59">59</a>]. The predictive value improves after 26 weeks of gestation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LLV</strong> – Fetuses that died had significantly larger LLV (10.5 versus 8) in one study [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Observed/expected LHR</strong> – This ratio is commonly used to predict outcome of fetuses with congenital diaphragmatic hernia, who typically have hypoplastic lung on the contralateral side. The use of O/E-LHR ratio in the assessment of outcome in the fetus with CPAM is less predictive of outcome, possibly due to more normal lung development on the contralateral side in the third trimester. In CPAM, a cutoff of 45 percent has a sensitivity of 73 percent and specificity of 68 percent for prediction of adverse outcome (perinatal death, pregnancy termination, hydrops, need for prenatal intervention [eg, pleural drainage and/or thoracocentesis], or need for postnatal respiratory assistance), with positive and negative predictive values of 0.52 and 0.84, respectively. Using a cutoff of 25 percent (which is associated with poorer prognosis in congenital diaphragmatic hernias) had low sensitivity (6 percent) but a positive predictive value of 1 and specificity of 100 percent [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/6800.html" rel="external">"Congenital diaphragmatic hernia: Prenatal issues", section on 'Lung area to head circumference ratio'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiomediastinal shift angle (CMSA) </strong>– Each 10-degree increase in CMSA increases the odds of an adverse perinatal outcome and hydrops [<a href="#rid31">31</a>]. The ability of CMSA to predict adverse perinatal outcome is optimized at a cutoff of 34.3 degrees (sensitivity 72 percent, specificity 85 percent), where its performance is comparable to the CVR. CMSA appears to be an alternative to CVR for evaluating CPAM lesions and predicting those that will have poor perinatal outcomes and thus can be useful when the CVR is difficult to measure or equivocal.</p><p></p><p class="headingAnchor" id="H5020104"><span class="h1">PREGNANCY MANAGEMENT</span><span class="headingEndMark"> — </span>In addition to routine prenatal care, we suggest the following.</p><p class="headingAnchor" id="H2955361886"><span class="h2">Genetic counseling</span><span class="headingEndMark"> — </span>The incidence of chromosomal abnormalities is not increased above baseline in fetuses with congenital pulmonary airway malformation (CPAM) alone; this should be considered when weighing the risks and benefits of invasive procedures for genetic studies. Microarray can be offered for further evaluation, and should be offered in cases with associated anomalies, as the frequency of genetic abnormalities is increased in fetuses with additional anomalies and/or nonimmune hydrops [<a href="#rid36">36</a>]. A case has been reported of an isolated CPAM associated with mosaic Klinefelter syndrome [<a href="#rid64">64</a>].</p><p>The genetic background of CPAM is not known, and associations with different genes have been suggested, incl<em>uding TTF-1</em> [<a href="#rid24">24</a>], <em>FABP-7</em> [<a href="#rid24">24</a>], <em>FGF-7</em>, <em>FGF-9</em>, <em>FGF-10</em>, <em>Hoxb-5</em>, and<em> SOX2</em> [<a href="#rid65">65</a>]. Abnormal<em> Hoxb-5</em> expression during human lung branching morphogenesis has been implicated in the development of CPAM [<a href="#rid66">66</a>]. Genetic assessment has shown a higher than expected number of mutations in cancer genes [<a href="#rid67">67,68</a>] and genetic analysis of resected tissue in a different cohort showed a clear association between CPAM type 1 and mucinous adenocarcinoma with KRAS point mutations [<a href="#rid69">69</a>]. </p><p>The American College of Medical Genetics and Genomics practice guidelines have recommended that exome and genome sequencing be considered as a first- or second-tier test for pediatric patients with congenital anomalies [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H3813732776"><span class="h2">Parental counseling</span><span class="headingEndMark"> — </span>Parental counseling includes:</p><p class="bulletIndent1"><span class="glyph">●</span>The differential diagnosis of prenatally suspected CPAM. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The possible course of the CPAM during pregnancy, including the possible growth patterns of the mass and risk for development of hydrops. CPAM volume ratio (CVR) &gt;1.6 is generally considered predictive of risk for hydrops, respiratory distress at birth, and probable need for early surgery. Hydrops associated with poor cardiac function is associated with a high risk for perinatal death. (See <a class="local">'Prenatal course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The majority of cases are managed conservatively, but the potential need for, and the options for, prenatal intervention (eg, <a class="drug drug_general" data-topicid="9139" href="/d/drug information/9139.html" rel="external">betamethasone</a>, cyst drainage, or thoracoamniotic shunting). (See <a class="local">'Second-line therapy: Invasive procedures'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Choosing an appropriate site for planned delivery, with consideration of the need for resources for newborn resuscitation and surgery. (See <a class="local">'Delivery'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postnatal issues (clinical manifestations, postnatal evaluation, postnatal management, potential complications (eg, infection, risk of malignancy), prognosis of associated anomalies, and range of outcomes). (See  <a class="medical medical_review" href="/d/html/6346.html" rel="external">"Congenital pulmonary airway malformation"</a>.)</p><p></p><p class="headingAnchor" id="H3210292455"><span class="h2">Follow-up imaging</span><span class="headingEndMark"> — </span>Serial prenatal ultrasound examinations are recommended every one to four weeks to assess change in size of the lung mass, change in CVR, and development of polyhydramnios and hydrops [<a href="#rid6">6,29</a>]. The frequency within this range depends on the gestational age and CVR. Closer follow-up should be performed in those patients at high risk of developing hydrops (eg, CVR ≥1.6, age &lt;26 weeks), whereas the interval between studies can be lengthened if the CPAM is very small (CVR &lt;0.91) [<a href="#rid30">30</a>], or growth has plateaued or is regressing, especially after 30 weeks of gestation [<a href="#rid71">71</a>]. When incipient hydrops is suspected because of fluid in one fetal compartment, assessment every two to three days may be reasonable. (See <a class="local">'Poor prognostic factors'</a> above.)</p><p class="headingAnchor" id="H1804499320"><span class="h1">MANAGEMENT OF THE HYDROPIC FETUS</span></p><p class="headingAnchor" id="H3837628216"><span class="h2">Delivery versus in utero treatment</span><span class="headingEndMark"> — </span>Hydrops is considered a high-risk scenario, thus requiring close observation with frequent cardiac assessment. Hydrops associated with heart failure is particularly prognostic for poor fetal outcome and therefore an indication for fetal intervention or delivery, depending on the gestational age [<a href="#rid6">6,8,14,27,38</a>]. No trials have compared the outcomes of delivery versus intervention. A reasonable approach is:</p><p class="bulletIndent1"><span class="glyph">●</span>For hydropic fetuses over 32 to 34 weeks of gestation, early delivery is probably the best option, with immediate postnatal resection [<a href="#rid6">6</a>]. Ex utero intrapartum therapy (EXIT) has been used to stabilize fetuses with large lesions expected to have difficulty breathing at birth [<a href="#rid72">72,73</a>]. (See <a class="local">'Delivery'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For hydropic fetuses between 20 and 32 weeks of gestation, the morbidity and mortality of preterm birth is a major concern so interventions to improve fetal hemodynamics and prevent lung hypoplasia have been investigated and appear to improve survival [<a href="#rid74">74,75</a>]. For example, small case series show good survival (&gt;90 percent) if hydrops resolves after maternal glucocorticoid therapy [<a href="#rid76">76</a>] and a systematic review found that prenatal drainage or resection improved survival of hydropic fetuses with primary hydrothoraces and/or congenital cystic lung lesions compared with hydropic controls who did not undergo these interventions (odds ratio 9, 95% CI 3-101) [<a href="#rid77">77</a>]. These options are discussed below. (See <a class="local">'Options for in utero treatment'</a> below.)</p><p></p><p class="headingAnchor" id="H69465567"><span class="h2">Options for in utero treatment</span></p><p class="headingAnchor" id="H5020278"><span class="h3">First-line therapy: Maternal betamethasone administration</span><span class="headingEndMark"> — </span>Steroids are the only medical option in the management of CPAM and have become the first-line therapy before 32 weeks in hydropic fetuses or fetuses determined to be at risk for developing hydrops because of CPAM volume ratio (CVR) &gt;1.6  (<a class="graphic graphic_diagnosticimage graphicRef127190" href="/d/graphic/127190.html" rel="external">image 7</a>). The therapeutic mechanism for resolution of hydrops is unknown, but it may be related to steroid-induced accelerated lung maturation or mass involution.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial dosing</strong> – A single standard course is administered to the mother: two doses of <a class="drug drug_general" data-topicid="9139" href="/d/drug information/9139.html" rel="external">betamethasone</a> 12 mg intramuscularly 24 hours apart.</p><p></p><p class="bulletIndent1">Ultrasound follow-up is performed weekly to evaluate the course of hydrops. The response to treatment is variable; fetuses with microcystic lesions appear to respond better than those with macrocystic lesions [<a href="#rid76">76,78-80</a>]. In three studies, including a total of 31 patients with microcystic disease and mean CVR of 2.5 treated with steroids, hydrops was present at steroid administration in 20 patients (65 percent), hydrops resolved in 16 of these 20 patients (80 percent), and 27 of the 31 patients (87 percent) survived [<a href="#rid76">76,78,79</a>]. In one of these studies, resolution of hydrops was noted in two cases as soon as five and nine days after steroid administration, but took two to five weeks in five cases, 13 weeks in one case, and did not resolve in the remaining two cases [<a href="#rid76">76</a>]. </p><p class="bulletIndent1">Although these results are better than generally reported in historic controls, some studies without administration of steroids have reported resolution of hydrops in 50 percent of fetuses and a 63 percent survival rate [<a href="#rid29">29,54</a>]. It is possible that fetal thoracic growth and/or CPAM regression rather than steroids accounted for the resolution of hydrops, particularly in those cases in which improvement did not occur for many weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repeated steroid dosing</strong> – Some fetuses who fail to respond to a single course of <a class="drug drug_general" data-topicid="9139" href="/d/drug information/9139.html" rel="external">betamethasone</a> will respond to additional courses, although not all fetuses respond to repeated courses of therapy. In retrospective studies, a substantial proportion of fetuses who did not respond to a first course of steroids stabilized or improved (eg, reduction in lesion size, resolving hydrops) after receiving two to three courses of therapy [<a href="#rid81">81,82</a>]. The median interval between the first and second course of steroids was approximately two weeks (range one to six weeks).</p><p></p><p class="bulletIndent1">Based on these findings, it is reasonable to administer one or two additional courses of <a class="drug drug_general" data-topicid="9139" href="/d/drug information/9139.html" rel="external">betamethasone</a> to fetuses with persistent elevated CVRs, lesion growth, or hydrops. The steroids are administered at intervals of at least one week following the previous steroid treatment. The use of additional courses of steroids versus invasive intervention depends on gestational age and severity of heart failure.</p><p></p><p class="headingAnchor" id="H2305341591"><span class="h3">Second-line therapy: Invasive procedures</span><span class="headingEndMark"> — </span>For fetuses &lt;32 weeks with hydrops or at risk for developing hydrops because of CPAM volume ratio (CVR) &gt;1.6 who do not respond to steroids, invasive intervention is the next option. The choice of the best invasive approach depends on the type of lesion (macrocystic versus microcystic). Patients being considered for cyst drainage should be managed by maternal-fetal medicine specialists with experience in invasive fetal procedures. </p><p>If not already evaluated, fetal microarray may be performed prior to initiating fetal therapy, given the increased risk for a genetic abnormality in hydropic fetuses (which may affect decision-making) and the cost and risk of invasive interventions [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H2183550882"><span class="h4">Choice of procedure</span><span class="headingEndMark"> — </span>Macrocystic CPAM can be managed with a drainage procedure [<a href="#rid49">49,84</a>]. A microcystic solid appearing CPAM is not amenable to shunting or cyst aspiration but can be managed by resection or ablation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drainage procedures</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cyst aspiration</strong> – Aspiration can decompress a large macrocyst and reverse the mediastinal shift [<a href="#rid49">49</a>]. Fluid reaccumulation limits its usefulness, but some fetuses will improve after one or two aspirations [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thoracentesis</strong> – While large effusions are rare in CPAM, thoracentesis has been described [<a href="#rid43">43</a>]. It is used as a temporizing maneuver to provide prognostic information when considering placement of a thoracoamniotic shunt [<a href="#rid6">6,32,45,77</a>]. Rapid reaccumulation of fluid limits its usefulness. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thoracoamniotic shunt</strong> – If the lesion is macrocystic with a dominant cyst and no large solid component, thoracoamniotic shunting may be a more definitive in utero solution than aspiration. Survival rates of 60 to 70 percent have been reported [<a href="#rid44">44,85</a>] and can be as high as 90 percent in nonhydropic fetuses [<a href="#rid86">86</a>]. However, the procedure results in a mild deformity of the chest wall in the majority of cases [<a href="#rid87">87</a>]. Prognostic factors associated with neonatal survival include resolution of hydrops after in utero therapy, reduction in mass volume, unilateral rather than bilateral effusion, and later gestational age at delivery [<a href="#rid85">85</a>]. </p><p></p><p class="bulletIndent2">Complications include displacement or malfunction of the catheter, preterm prelabor rupture of membranes, and preterm labor [<a href="#rid32">32</a>]. Rarely, fetal hemorrhage, procedure-related abruption, and thrombus occlusion of the catheter have been reported. An internally displaced catheter has been associated with trauma to the fetal chest wall (especially if the procedure is performed before 20 weeks) and with refractory tension pneumothorax postnatally [<a href="#rid44">44,88</a>]. </p><p></p><p class="bulletIndent2">A long-term assessment (median of 11 years) of patients with congenital lung malformations treated with fetal thoracoamniotic shunt placement demonstrated preserved respiratory capacity and exercise tolerance [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alcohol ablation</strong> – Alcohol ablation is used for large cystic lesions as well as microcystic lesions. For large lesions, ethanol is instilled and then withdrawn after five minutes. For microcystic lesions small volumes of ethanol are instilled at multiple locations and cannot be withdrawn. Complications from ethanol spillage can result in chest wall anomalies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Open resection</strong> — Open fetal surgery with resection of solid or mixed solid/cystic CPAM with a large solid component has been reported to be successful in approximately 50 percent of cases but has risk to both the mother and the fetus. The surgical team needs to optimize maternal anesthesia, uterine relaxation, hysterotomy technique, fetal exposure, and intraoperative fetal monitoring, as well as be experienced in reapproximation of the fetal membranes and uterine incision. Close postoperative follow-up is critical for early detection and treatment of maternal and fetal complications.</p><p></p><p class="bulletIndent1">Following resection, hydrops resolves over one to two weeks with reversal of the mediastinal shift over three weeks [<a href="#rid44">44</a>]. In one study, surgical resection of the mass (fetal lobectomy) was performed in 13 hydropic fetuses at 21 to 29 weeks of gestation [<a href="#rid6">6</a>]. Hydrops resolved in eight fetuses (61 percent), with good subsequent in utero lung growth and neonatal survival. There were four intraoperative or postprocedure fetal deaths, and one newborn delivered one week after the procedure died within 48 hours of birth of pulmonary hypoplasia. A smaller series reported survival in only two of seven fetuses [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1">Maternal-fetal surgery requiring hysterotomy is associated with an increased risk of serious complications in the current pregnancy (preterm labor, preterm prelabor rupture of membranes, uterine dehiscence or rupture) [<a href="#rid44">44</a>], as well as an increased risk of uterine rupture or dehiscence in subsequent pregnancies [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational procedures</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Percutaneous laser ablation</strong> – A few case reports have described percutaneous laser ablation of solid CPAM [<a href="#rid44">44,90-94</a>]. Mass size decreased in one series, with complete resolution of fetal hydrops in four of seven cases, but only two fetuses survived [<a href="#rid90">90</a>]. Additional studies are needed to determine whether this a valid therapeutic option.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Percutaneous sclerotherapy</strong> – Percutaneous injection of <a class="drug drug_general" data-topicid="9431" href="/d/drug information/9431.html" rel="external">ethanolamine oleate</a> or <a class="drug drug_general" data-topicid="9907" href="/d/drug information/9907.html" rel="external">polidocanol</a> into a large solid CPAM under ultrasound guidance is another option. One study attempted fetal sclerotherapy in three patients under 26 weeks of gestation with CPAM and hydrops, severe mediastinal shift, and polyhydramnios, with resolution of the mass effect and hydrops in all cases [<a href="#rid95">95</a>]. In another series of eight patients and hydrops who underwent sclerotherapy, four fetuses died and four survived to term and underwent postnatal resection [<a href="#rid96">96</a>]. </p><p></p><p class="bulletIndent2">Percutaneous administration of a sclerosing agent can also be used for cystic lesions [<a href="#rid97">97</a>]. In macrocystic cases, the sclerosing agent is instilled and then withdrawn after five minutes. In microcystic lesions, small volumes of the sclerosing agent are instilled at multiple locations but cannot be withdrawn. Spillage of the sclerosing agent can result in chest wall anomalies.</p><p></p><p class="headingAnchor" id="H5020690"><span class="h1">DELIVERY</span></p><p class="headingAnchor" id="H2290462481"><span class="h2">Planning</span><span class="headingEndMark"> — </span>Birth planning should be in conjunction with the pediatric staff (neonatology, pediatric surgery) [<a href="#rid98">98</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Small CPAM – If the lung mass has resolved or is small with no mediastinal shift or hydrops, CPAM itself is not an indication for early delivery or cesarean birth [<a href="#rid44">44,99,100</a>]. Neonatal respiratory problems would be unlikely.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Large CPAM – For fetuses with large masses that cause mediastinal shift and/or hydrops, birth should be planned for a tertiary care center with an intensive care nursery capable of resuscitating a neonate with respiratory problems (including extracorporeal membrane oxygenation [ECMO] capability) and with available pediatric surgeons experienced in care of these infants [<a href="#rid32">32,48</a>]. When a large mass is present, immediate thoracotomy in the delivery room may need to be performed to relieve lung compression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate CPAM – In masses that are intermediate in size, a CPAM volume ratio (CVR) &gt;1 predicts increased risk of neonatal respiratory problems and thus the need for substantial newborn support in the delivery room [<a href="#rid101">101</a>].</p><p></p><p class="headingAnchor" id="H2644458952"><span class="h2">Ex utero intrapartum therapy (EXIT) procedure</span><span class="headingEndMark"> — </span>EXIT has been used to improve outcome of exceptionally large lung lesions [<a href="#rid48">48</a>]. If a large CPAM connects to the bronchial airway, the neonates initial respirations can fill the CPAM with air but it will not decompress, which can result in an expanding intrathoracic mass that can compress the heart and behave like a tension pneumothorax.</p><p>In EXIT, the fetus is partially delivered and intubated without clamping the umbilical cord. Uteroplacental blood flow and gas exchange are maintained by using inhalational agents to provide uterine relaxation and amnioinfusion to maintain uterine volume and to avoid uterine collapse that could result in placental separation and/or cord compression. This provides time for cannulation for ECMO and chest decompression before delivery of the fetus and allows for delayed removal of the CPAM. In rare instances, the lung mass can be excised before completing delivery.</p><p>Overall fetal/newborn survival of 90 percent has been reported [<a href="#rid44">44</a>]. However, the risk of maternal bleeding is increased, and 13 percent of mothers need transfusion [<a href="#rid102">102,103</a>].</p><p class="headingAnchor" id="H1308279675"><span class="h1">POSTNATAL MANAGEMENT</span><span class="headingEndMark"> — </span>Postnatal management of symptomatic CPAM is surgical resection, with timing dependent on severity of symptoms [<a href="#rid49">49</a>]. The treatment for asymptomatic CPAM remains controversial. Postnatal presentation, evaluation, complications, and management are discussed separately. (See  <a class="medical medical_review" href="/d/html/6346.html" rel="external">"Congenital pulmonary airway malformation"</a>.)</p><p class="headingAnchor" id="H5020792"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anatomy</strong> – Prenatally, congenital pulmonary airway malformation (CPAM) is classified as microcystic (74 percent) or macrocystic (26 percent), although mixed lesions also occur. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prenatal diagnosis </strong>– Prenatal diagnosis is most commonly based on ultrasound findings first detected in the second trimester. (See <a class="local">'Prenatal diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Macrocystic CPAM is characterized by the presence of anechoic cysts &gt;5 mm in diameter, often surrounded by hyperechogenic lung parenchyma  (<a class="graphic graphic_diagnosticimage graphicRef64147" href="/d/graphic/64147.html" rel="external">image 3</a>) (type I).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Microcystic CPAM is characterized by the presence of a solid-appearing homogeneous mass that is hyperechogenic compared with adjacent normal lung parenchyma, and composed of microcystic lesions &lt;5 mm in diameter  (<a class="graphic graphic_diagnosticimage graphicRef77848" href="/d/graphic/77848.html" rel="external">image 4</a>) (type III). As gestational age increases, microcystic lesions can become more difficult to visualize due to increased echogenicity of surrounding normal lung [<a href="#rid16">16</a>]. Increased shadowing from overlying ribs also makes assessment of the mass more difficult in the third trimester.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mixed CPAM lesions contain both solid and cystic components  (<a class="graphic graphic_diagnosticimage graphicRef71008" href="/d/graphic/71008.html" rel="external">image 5</a>) (type II).</p><p></p><p class="bulletIndent1">On color and power Doppler, the arterial supply and venous drainage are from the pulmonary circulation. If a systemic feeding vessel is noted, the lesion is considered a bronchopulmonary sequestration (BPS) if solid and a hybrid BPS/CPAM lesion if cystic and solid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postdiagnostic evaluation</strong> – Initial evaluation should include assessment for other congenital anomalies. Genetic background of CPAM is not known, but associations with different genes has been suggested, including some associated with increased cancer risk. Microarray can be offered for further evaluation, and should be offered in cases with associated anomalies, as the frequency of genetic abnormalities is increased in fetuses with additional anomalies and/or nonimmune hydrops. The American College of Medical Genetics and Genomics practice guidelines recommend exome and genome sequencing as second-tier tests for pediatric patients with congenital anomalies. (See <a class="local">'Postdiagnostic imaging evaluation'</a> above.)</p><p></p><p class="bulletIndent1">Echocardiography is useful to assess for congenital heart disease and outcome if hydrops develops. Magnetic resonance imaging (MRI) is used to better delineate abnormal and normal anatomy when the entire lung is involved by the mass, in the presence of hydrops or bilateral lesions, and when the diagnosis is uncertain. (See <a class="local">'Role of magnetic resonance imaging'</a> above.)</p><p></p><p class="bulletIndent1">We suggest serial prenatal ultrasound examinations every one to four weeks to assess change in size of the lung mass, change in CPAM volume ratio (CVR), and development of polyhydramnios and hydrops. The frequency within this range depends on the gestational age and CVR. Closer follow-up should be performed in those patients at high risk of developing hydrops (eg, CVR ≥1.6, age &lt;26 weeks), whereas the interval between studies can be lengthened if the CPAM is very small (CVR &lt;0.91) [<a href="#rid30">30</a>], or growth has plateaued or is regressing, especially after 30 weeks of gestation. (See <a class="local">'Follow-up imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prenatal course </strong>– Most CPAMs demonstrate rapid progressive growth from approximately weeks 20 to 26 of gestation, peaking at approximately 25 weeks, and then growth plateaus and often regresses. Fetuses with large masses can develop hydrops, which has a poor prognosis in the absence of intervention. If hydrops has not developed by 28 weeks, it is unlikely to develop and the prognosis is excellent, with reported live birth rates ≥95 percent. Prenatal course can be predicted by quantitative measurements, such as the CVR, mass-to-thorax ratio (MTR), lung mass volume ratio (LMVR), observed/expected lung-to-head ratio (LHR), and cardiomediastinal shift angle (CMSA). (See <a class="local">'Prenatal course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of hydrops</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For hydropic fetuses over 32 to 34 weeks of gestation, we suggest delivery with immediate postnatal resection rather than in utero treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Management of the hydropic fetus'</a> above.).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For hydropic fetuses 20 to 32 weeks, we recommend maternal administration of <a class="drug drug_general" data-topicid="9139" href="/d/drug information/9139.html" rel="external">betamethasone</a> (12 mg intramuscularly, two doses 24 hours apart) rather than delivery or expectant management (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). Better responses have been noted with microcystic compared with macrocystic CPAM. Some fetuses who fail to respond to a single course of betamethasone respond to additional courses. (See <a class="local">'First-line therapy: Maternal betamethasone administration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Interventional procedures such as cyst drainage and placement of a thoracoamniotic shunt are invasive options for refractory cases of macrocystic CPAM with hydrops remote from term. These procedures are not options for microcystic CPAM. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Open resection is the most invasive option, and can be used for solid or mixed solid/cystic CPAM with a large solid component with refractory hydrops remote from term, but has risk to both the mother and the fetus. (See <a class="local">'Second-line therapy: Invasive procedures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delivery</strong> – Delivery planning should be in conjunction with the pediatric staff (neonatology, pediatric surgery). If the lung mass has resolved or is small with no mediastinal shift or hydrops, CPAM itself is not an indication for early delivery or cesarean birth. Neonatal respiratory problems would be unlikely.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For fetuses with large masses that cause mediastinal shift and/or hydrops, delivery should be planned for a tertiary care center with an intensive care nursery capable of resuscitation of a neonate with respiratory difficulties, including capability of extracorporeal membrane oxygenation (ECMO), and with pediatric surgeons experienced in care of these infants.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For masses that are not large or small, a CVR &gt;1 can help predict the risk of neonatal respiratory problems and, in turn, the most appropriate site for delivery. (See <a class="local">'Delivery'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Abbey P, Narula MK, Anand R. Congenital Malformations and Developmental Anomalies of the Lung. Curr Radiol Rep 2014; 2:71.</a></li><li><a class="nounderline abstract_t">Gupta K, Das A, Menon P, et al. Revisiting the histopathologic spectrum of congenital pulmonary developmental disorders. Fetal Pediatr Pathol 2012; 31:74.</a></li><li><a class="nounderline abstract_t">Panicek DM, Heitzman ER, Randall PA, et al. The continuum of pulmonary developmental anomalies. Radiographics 1987; 7:747.</a></li><li><a class="nounderline abstract_t">Swarr DT, Peranteau WH, Pogoriler J, et al. Novel Molecular and Phenotypic Insights into Congenital Lung Malformations. Am J Respir Crit Care Med 2018; 197:1328.</a></li><li><a class="nounderline abstract_t">Barazzone-Argiroffo C, Lascano Maillard J, Vidal I, et al. New insights on congenital pulmonary airways malformations revealed by proteomic analyses. Orphanet J Rare Dis 2019; 14:272.</a></li><li><a class="nounderline abstract_t">Adzick NS, Harrison MR, Crombleholme TM, et al. Fetal lung lesions: management and outcome. Am J Obstet Gynecol 1998; 179:884.</a></li><li><a class="nounderline abstract_t">Stocker JT. Congenital pulmonary airway malformation - a new name for and an expanded classification of congenital cystic adenomatoid malformation of the lung. Histopathology 2002; 41:424.</a></li><li><a class="nounderline abstract_t">Bulas D. Fetal magnetic resonance imaging as a complement to fetal ultrasonography. Ultrasound Q 2007; 23:3.</a></li><li><a class="nounderline abstract_t">Pacharn P, Kline-Fath B, Calvo-Garcia M, et al. Congenital lung lesions: prenatal MRI and postnatal findings. Pediatr Radiol 2013; 43:1136.</a></li><li><a class="nounderline abstract_t">Breysem L, Bosmans H, Dymarkowski S, et al. The value of fast MR imaging as an adjunct to ultrasound in prenatal diagnosis. Eur Radiol 2003; 13:1538.</a></li><li><a class="nounderline abstract_t">Quinn TM, Hubbard AM, Adzick NS. Prenatal magnetic resonance imaging enhances fetal diagnosis. J Pediatr Surg 1998; 33:553.</a></li><li><a class="nounderline abstract_t">Lee J, Seong HS, Kim BJ, et al. Evidence to support that spontaneous preterm labor is adaptive in nature: neonatal RDS is more common in "indicated" than in "spontaneous" preterm birth. J Perinat Med 2009; 37:53.</a></li><li><a class="nounderline abstract_t">Adams NC, Victoria T, Oliver ER, et al. Fetal ultrasound and magnetic resonance imaging: a primer on how to interpret prenatal lung lesions. Pediatr Radiol 2020; 50:1839.</a></li><li><a class="nounderline abstract_t">Hubbard AM, Adzick NS, Crombleholme TM, et al. Congenital chest lesions: diagnosis and characterization with prenatal MR imaging. Radiology 1999; 212:43.</a></li><li><a class="nounderline abstract_t">Ruano R, Joubin L, Aubry MC, et al. A nomogram of fetal lung volumes estimated by 3-dimensional ultrasonography using the rotational technique (virtual organ computer-aided analysis). J Ultrasound Med 2006; 25:701.</a></li><li><a class="nounderline abstract_t">Levine D, Barnewolt CE, Mehta TS, et al. Fetal thoracic abnormalities: MR imaging. Radiology 2003; 228:379.</a></li><li><a class="nounderline abstract_t">Victoria T, Srinivasan AS, Pogoriler J, et al. The rare solid fetal lung lesion with T2-hypointense components: prenatal imaging findings with postnatal pathological correlation. Pediatr Radiol 2018; 48:1556.</a></li><li><a class="nounderline abstract_t">Riedlinger WF, Vargas SO, Jennings RW, et al. Bronchial atresia is common to extralobar sequestration, intralobar sequestration, congenital cystic adenomatoid malformation, and lobar emphysema. Pediatr Dev Pathol 2006; 9:361.</a></li><li><a class="nounderline abstract_t">Ankermann T, Oppermann HC, Engler S, et al. Congenital masses of the lung, cystic adenomatoid malformation versus congenital lobar emphysema: prenatal diagnosis and implications for postnatal treatment. J Ultrasound Med 2004; 23:1379.</a></li><li><a class="nounderline abstract_t">Maas KL, Feldstein VA, Goldstein RB, Filly RA. Sonographic detection of bilateral fetal chest masses: report of three cases. J Ultrasound Med 1997; 16:647.</a></li><li><a class="nounderline abstract_t">Azizkhan RG, Crombleholme TM. Congenital cystic lung disease: contemporary antenatal and postnatal management. Pediatr Surg Int 2008; 24:643.</a></li><li><a class="nounderline abstract_t">Schott S, Mackensen-Haen S, Wallwiener M, et al. Cystic adenomatoid malformation of the lung causing hydrops fetalis: case report and review of the literature. Arch Gynecol Obstet 2009; 280:293.</a></li><li class="breakAll">Stocker, T, Dehner, LP. Pediatric Pathology, 2nd ed, Lippincott Williams and Wilkins,  p.473.</li><li><a class="nounderline abstract_t">Pizzi M, Fassan M, Ludwig K, et al. Congenital pulmonary airway malformation (CPAM) [congenital cystic adenomatoid malformation] associated with tracheoesophageal fistula and agensesis of the corpus callosum. Fetal Pediatr Pathol 2012; 31:169.</a></li><li><a class="nounderline abstract_t">Millington KA, Mani H. Type 2 congenital pulmonary airway malformation and congenital nephrotic syndrome: report of a new association. Pediatr Dev Pathol 2013; 16:210.</a></li><li><a class="nounderline abstract_t">Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation 2014; 129:2183.</a></li><li><a class="nounderline abstract_t">Cass DL, Olutoye OO, Ayres NA, et al. Defining hydrops and indications for open fetal surgery for fetuses with lung masses and vascular tumors. J Pediatr Surg 2012; 47:40.</a></li><li><a class="nounderline abstract_t">Hofstaetter C, Hansmann M, Eik-Nes SH, et al. A cardiovascular profile score in the surveillance of fetal hydrops. J Matern Fetal Neonatal Med 2006; 19:407.</a></li><li><a class="nounderline abstract_t">Crombleholme TM, Coleman B, Hedrick H, et al. Cystic adenomatoid malformation volume ratio predicts outcome in prenatally diagnosed cystic adenomatoid malformation of the lung. J Pediatr Surg 2002; 37:331.</a></li><li><a class="nounderline abstract_t">Hellmund A, Berg C, Geipel A, et al. Prenatal Diagnosis and Evaluation of Sonographic Predictors for Intervention and Adverse Outcome in Congenital Pulmonary Airway Malformation. PLoS One 2016; 11:e0150474.</a></li><li><a class="nounderline abstract_t">Shulman R, Sparks TN, Gosnell K, et al. Fetal Congenital Pulmonary Airway Malformation: The Role of an Objective Measurement of Cardiomediastinal Shift. Am J Perinatol 2019; 36:225.</a></li><li><a class="nounderline abstract_t">Mann S, Wilson RD, Bebbington MW, et al. Antenatal diagnosis and management of congenital cystic adenomatoid malformation. Semin Fetal Neonatal Med 2007; 12:477.</a></li><li><a class="nounderline abstract_t">Zeidan S, Gorincour G, Potier A, et al. Congenital lung malformation: evaluation of prenatal and postnatal radiological findings. Respirology 2009; 14:1005.</a></li><li><a class="nounderline abstract_t">Flanagan S, Rubesova E, Hintz S, et al. Prenatal imaging of bronchopulmonary malformations: Is there a role for late third trimester fetal MRI? Pediatr Radiol 2013; 43:205.</a></li><li><a class="nounderline abstract_t">Hong C, Yu G, Tang J, et al. Risk analysis and outcomes of bronchopulmonary sequestrations. Pediatr Surg Int 2017; 33:971.</a></li><li><a class="nounderline abstract_t">Bush A, Hogg J, Chitty LS. Cystic lung lesions - prenatal diagnosis and management. Prenat Diagn 2008; 28:604.</a></li><li><a class="nounderline abstract_t">Perea L, Blinman T, Piccione J, Laje P. Bilateral congenital lobar emphysema: staged management. J Pediatr Surg 2017; 52:1442.</a></li><li><a class="nounderline abstract_t">Daltro P, Werner H, Gasparetto TD, et al. Congenital chest malformations: a multimodality approach with emphasis on fetal MR imaging. Radiographics 2010; 30:385.</a></li><li><a class="nounderline abstract_t">Seo T, Ando H, Kaneko K, et al. Two cases of prenatally diagnosed congenital lobar emphysema caused by lobar bronchial atresia. J Pediatr Surg 2006; 41:e17.</a></li><li><a class="nounderline abstract_t">Kumar AN. Perinatal management of common neonatal thoracic lesions. Indian J Pediatr 2008; 75:931.</a></li><li><a class="nounderline abstract_t">Richards DS, Kays DM. Fetal umbilical vein deviation in congenital diaphragmatic hernia. J Ultrasound Med 2013; 32:263.</a></li><li><a class="nounderline abstract_t">Gowda M, Gupta S, Ali A, Paranthaman S. Locating the Level and Extent of Congenital High Airway Obstruction: Fluid in the Airway Tract as Reference Points. J Ultrasound Med 2017; 36:2179.</a></li><li><a class="nounderline abstract_t">Gosavi M, Kumar L, Ratnakar A, Bannur H. Congenital High Airway Obstruction Syndrome (CHAOS): A perinatal autopsy case report. Pathol Res Pract 2017; 213:170.</a></li><li><a class="nounderline abstract_t">Wilson RD. In utero therapy for fetal thoracic abnormalities. Prenat Diagn 2008; 28:619.</a></li><li><a class="nounderline abstract_t">Nasr A, Himidan S, Pastor AC, et al. Is congenital cystic adenomatoid malformation a premalignant lesion for pleuropulmonary blastoma? J Pediatr Surg 2010; 45:1086.</a></li><li><a class="nounderline abstract_t">Mechoulan A, Leclair MD, Yvinec M, et al. [Pleuropulmonary blastoma: a case of early neonatal diagnosis through antenatal scan screening]. Gynecol Obstet Fertil 2007; 35:437.</a></li><li><a class="nounderline abstract_t">Dishop MK, McKay EM, Kreiger PA, et al. Fetal lung interstitial tumor (FLIT): A proposed newly recognized lung tumor of infancy to be differentiated from cystic pleuropulmonary blastoma and other developmental pulmonary lesions. Am J Surg Pathol 2010; 34:1762.</a></li><li><a class="nounderline abstract_t">Adzick NS. Open fetal surgery for life-threatening fetal anomalies. Semin Fetal Neonatal Med 2010; 15:1.</a></li><li><a class="nounderline abstract_t">Downard CD, Calkins CM, Williams RF, et al. Treatment of congenital pulmonary airway malformations: a systematic review from the APSA outcomes and evidence based practice committee. Pediatr Surg Int 2017; 33:939.</a></li><li><a class="nounderline abstract_t">Cook J, Chitty LS, De Coppi P, et al. The natural history of prenatally diagnosed congenital cystic lung lesions: long-term follow-up of 119 cases. Arch Dis Child 2017; 102:798.</a></li><li><a class="nounderline abstract_t">Stewart DR, Best AF, Williams GM, et al. Neoplasm Risk Among Individuals With a Pathogenic Germline Variant in DICER1. J Clin Oncol 2019; 37:668.</a></li><li><a class="nounderline abstract_t">Haider F, Al Saad K, Al-Hashimi F, Al-Hashimi H. It's Rare So Be Aware: Pleuropulmonary Blastoma Mimicking Congenital Pulmonary Airway Malformation. Thorac Cardiovasc Surg Rep 2017; 6:e10.</a></li><li><a class="nounderline abstract_t">Phillips J, Blask A, DiPoto Brahmbhatt A, et al. Fetal lung interstitial tumor: Prenatal presentation of a rare fetal malignancy. J Neonatal Perinatal Med 2019; 12:473.</a></li><li><a class="nounderline abstract_t">Kunisaki SM, Barnewolt CE, Estroff JA, et al. Large fetal congenital cystic adenomatoid malformations: growth trends and patient survival. J Pediatr Surg 2007; 42:404.</a></li><li><a class="nounderline abstract_t">Kunisaki SM, Fauza DO, Barnewolt CE, et al. Ex utero intrapartum treatment with placement on extracorporeal membrane oxygenation for fetal thoracic masses. J Pediatr Surg 2007; 42:420.</a></li><li><a class="nounderline abstract_t">Cavoretto P, Molina F, Poggi S, et al. Prenatal diagnosis and outcome of echogenic fetal lung lesions. Ultrasound Obstet Gynecol 2008; 32:769.</a></li><li><a class="nounderline abstract_t">Kunisaki SM, Ehrenberg-Buchner S, Dillman JR, et al. Vanishing fetal lung malformations: Prenatal sonographic characteristics and postnatal outcomes. J Pediatr Surg 2015; 50:978.</a></li><li><a class="nounderline abstract_t">King A, Lee TC, Steen E, et al. Prenatal Imaging to Predict Need for Urgent Perinatal Surgery in Congenital Lung Lesions. J Surg Res 2020; 255:463.</a></li><li><a class="nounderline abstract_t">Zamora IJ, Sheikh F, Cassady CI, et al. Fetal MRI lung volumes are predictive of perinatal outcomes in fetuses with congenital lung masses. J Pediatr Surg 2014; 49:853.</a></li><li><a class="nounderline abstract_t">Raychaudhuri P, Pasupati A, James A, et al. Prospective study of antenatally diagnosed congenital cystic adenomatoid malformations. Pediatr Surg Int 2011; 27:1159.</a></li><li><a class="nounderline abstract_t">Costanzo S, Filisetti C, Vella C, et al. Pulmonary Malformations: Predictors of Neonatal Respiratory Distress and Early Surgery. J Neonatal Surg 2016; 5:27.</a></li><li><a class="nounderline abstract_t">Kane SC, Ancona E, Reidy KL, Palma-Dias R. The Utility of the Congenital Pulmonary Airway Malformation-Volume Ratio in the Assessment of Fetal Echogenic Lung Lesions: A Systematic Review. Fetal Diagn Ther 2020; 47:171.</a></li><li><a class="nounderline abstract_t">Ehrenberg-Buchner S, Stapf AM, Berman DR, et al. Fetal lung lesions: can we start to breathe easier? Am J Obstet Gynecol 2013; 208:151.e1.</a></li><li><a class="nounderline abstract_t">Holubyeva A, Bracero LA, Feuerstein JL, Bush S. Congenital pulmonary airway malformation associated with mosaic Klinefelter syndrome. J Clin Ultrasound 2020; 48:121.</a></li><li><a class="nounderline abstract_t">David M, Lamas-Pinheiro R, Henriques-Coelho T. Prenatal and Postnatal Management of Congenital Pulmonary Airway Malformation. Neonatology 2016; 110:101.</a></li><li><a class="nounderline abstract_t">Volpe MV, Pham L, Lessin M, et al. Expression of Hoxb-5 during human lung development and in congenital lung malformations. Birth Defects Res A Clin Mol Teratol 2003; 67:550.</a></li><li><a class="nounderline abstract_t">Hsu JS, Zhang R, Yeung F, et al. Cancer gene mutations in congenital pulmonary airway malformation patients. ERJ Open Res 2019; 5.</a></li><li><a class="nounderline abstract_t">Tam PK. Whole exome sequencing to uncover genetic variants underlying congenital cystic adenomatoid malformations. Hong Kong Med J 2019; 25 Suppl 5:36.</a></li><li><a class="nounderline abstract_t">Muntean A, Banias LE, Ade-Ajayi N, et al. Neonatal congenital pulmonary airway malformation associated with mucinous adenocarcinoma and KRAS mutations. J Pediatr Surg 2022; 57:520.</a></li><li><a class="nounderline abstract_t">Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2021; 23:2029.</a></li><li><a class="nounderline abstract_t">Coleman BG, Adzick NS, Crombleholme TM, et al. Fetal therapy: state of the art. J Ultrasound Med 2002; 21:1257.</a></li><li><a class="nounderline abstract_t">Liechty KW. Ex-utero intrapartum therapy. Semin Fetal Neonatal Med 2010; 15:34.</a></li><li><a class="nounderline abstract_t">Hedrick HL, Flake AW, Crombleholme TM, et al. The ex utero intrapartum therapy procedure for high-risk fetal lung lesions. J Pediatr Surg 2005; 40:1038.</a></li><li><a class="nounderline abstract_t">Lecomte B, Hadden H, Coste K, et al. Hyperechoic congenital lung lesions in a non-selected population: from prenatal detection till perinatal management. Prenat Diagn 2009; 29:1222.</a></li><li><a class="nounderline abstract_t">Witlox RS, Lopriore E, Oepkes D. Prenatal interventions for fetal lung lesions. Prenat Diagn 2011; 31:628.</a></li><li><a class="nounderline abstract_t">Curran PF, Jelin EB, Rand L, et al. Prenatal steroids for microcystic congenital cystic adenomatoid malformations. J Pediatr Surg 2010; 45:145.</a></li><li><a class="nounderline abstract_t">Knox EM, Kilby MD, Martin WL, Khan KS. In-utero pulmonary drainage in the management of primary hydrothorax and congenital cystic lung lesion: a systematic review. Ultrasound Obstet Gynecol 2006; 28:726.</a></li><li><a class="nounderline abstract_t">Morris LM, Lim FY, Livingston JC, et al. High-risk fetal congenital pulmonary airway malformations have a variable response to steroids. J Pediatr Surg 2009; 44:60.</a></li><li><a class="nounderline abstract_t">Peranteau WH, Wilson RD, Liechty KW, et al. Effect of maternal betamethasone administration on prenatal congenital cystic adenomatoid malformation growth and fetal survival. Fetal Diagn Ther 2007; 22:365.</a></li><li><a class="nounderline abstract_t">Loh KC, Jelin E, Hirose S, et al. Microcystic congenital pulmonary airway malformation with hydrops fetalis: steroids vs open fetal resection. J Pediatr Surg 2012; 47:36.</a></li><li><a class="nounderline abstract_t">Derderian SC, Coleman AM, Jeanty C, et al. Favorable outcomes in high-risk congenital pulmonary airway malformations treated with multiple courses of maternal betamethasone. J Pediatr Surg 2015; 50:515.</a></li><li><a class="nounderline abstract_t">Peranteau WH, Boelig MM, Khalek N, et al. Effect of single and multiple courses of maternal betamethasone on prenatal congenital lung lesion growth and fetal survival. J Pediatr Surg 2016; 51:28.</a></li><li><a class="nounderline abstract_t">Adzick NS. Management of fetal lung lesions. Clin Perinatol 2009; 36:363.</a></li><li><a class="nounderline abstract_t">Jeong BD, An SA, Lee MY, et al. Comparison of the Prognostic Factors of Fetuses With Congenital Pulmonary Airway Malformations According to Type. J Ultrasound Med 2020; 39:2243.</a></li><li><a class="nounderline abstract_t">Peranteau WH, Adzick NS, Boelig MM, et al. Thoracoamniotic shunts for the management of fetal lung lesions and pleural effusions: a single-institution review and predictors of survival in 75 cases. J Pediatr Surg 2015; 50:301.</a></li><li><a class="nounderline abstract_t">Litwińska M, Litwińska E, Janiak K, et al. Thoracoamniotic Shunts in Macrocystic Lung Lesions: Case Series and Review of the Literature. Fetal Diagn Ther 2017; 41:179.</a></li><li><a class="nounderline abstract_t">Muntean A, Cazacu R, Ade-Ajayi N, et al. The long-term outcome following thoraco-amniotic shunting for congenital lung malformations. J Pediatr Surg 2023; 58:213.</a></li><li><a class="nounderline abstract_t">Law BH, Bratu I, Jain V, Landry MA. Refractory tension pneumothorax as a result of an internally displaced thoracoamniotic shunt in an infant with a congenital pulmonary airway malformation. BMJ Case Rep 2016; 2016.</a></li><li><a class="nounderline abstract_t">Goodnight WH, Bahtiyar O, Bennett KA, et al. Subsequent pregnancy outcomes after open maternal-fetal surgery for myelomeningocele. Am J Obstet Gynecol 2019; 220:494.e1.</a></li><li><a class="nounderline abstract_t">Bruner JP, Jarnagin BK, Reinisch L. Percutaneous laser ablation of fetal congenital cystic adenomatoid malformation: too little, too late? Fetal Diagn Ther 2000; 15:359.</a></li><li><a class="nounderline abstract_t">Fortunato S. Intrauterine laser ablation of a fetal cystic adenomatoid malformation with hydrops: the application of minimally invasive surgical techniques to fetal surgery. Am J Obstet Gynecol 1997; 176:S84.</a></li><li><a class="nounderline abstract_t">Ong SS, Chan SY, Ewer AK, et al. Laser ablation of foetal microcystic lung lesion: successful outcome and rationale for its use. Fetal Diagn Ther 2006; 21:471.</a></li><li><a class="nounderline abstract_t">Ruano R, da Silva MM, Salustiano EM, et al. Percutaneous laser ablation under ultrasound guidance for fetal hyperechogenic microcystic lung lesions with hydrops: a single center cohort and a literature review. Prenat Diagn 2012; 32:1127.</a></li><li><a class="nounderline abstract_t">Klinkner DB, Atwell T, Teles Abrao Trad A, et al. Innovative Fetal Therapy for a Giant Congenital Pulmonary Airway Malformation with Hydrops. Fetal Diagn Ther 2022; 49:250.</a></li><li><a class="nounderline abstract_t">Bermúdez C, Pérez-Wulff J, Arcadipane M, et al. Percutaneous fetal sclerotherapy for congenital cystic adenomatoid malformation of the lung. Fetal Diagn Ther 2008; 24:237.</a></li><li><a class="nounderline abstract_t">Chon AH, Korst LM, Abdel-Sattar M, et al. Types II and III congenital pulmonary airway malformation with hydrops treated in utero with percutaneous sclerotherapy. Prenat Diagn 2018; 38:493.</a></li><li><a class="nounderline abstract_t">Kohl T. Lifesaving Treatments for the Tiniest Patients-A Narrative Description of Old and New Minimally Invasive Approaches in the Arena of Fetal Surgery. Children (Basel) 2022; 10.</a></li><li><a class="nounderline abstract_t">Kunisaki SM, Saito JM, Fallat ME, et al. Fetal Risk Stratification and Outcomes in Children with Prenatally Diagnosed Lung Malformations: Results from a Multi-Institutional Research Collaborative. Ann Surg 2022; 276:e622.</a></li><li><a class="nounderline abstract_t">Marshall KW, Blane CE, Teitelbaum DH, van Leeuwen K. Congenital cystic adenomatoid malformation: impact of prenatal diagnosis and changing strategies in the treatment of the asymptomatic patient. AJR Am J Roentgenol 2000; 175:1551.</a></li><li><a class="nounderline abstract_t">Berman L, Jackson J, Miller K, et al. Expert surgical consensus for prenatal counseling using the Delphi method. J Pediatr Surg 2018; 53:1592.</a></li><li><a class="nounderline abstract_t">Mehl SC, Short WD, Kinley A, et al. Delivery planning for congenital lung malformations: A CVR based perinatal care algorithm. J Pediatr Surg 2022; 57:833.</a></li><li><a class="nounderline abstract_t">Novoa RH, Quintana W, Castillo-Urquiaga W, Ventura W. EXIT (ex utero intrapartum treatment) surgery for the management of fetal airway obstruction: A systematic review of the literature. J Pediatr Surg 2020; 55:1188.</a></li><li><a class="nounderline abstract_t">Shamshirsaz AA, Aalipour S, Erfani H, et al. Obstetric outcomes of ex-utero intrapartum treatment (EXIT). Prenat Diagn 2019; 39:643.</a></li></ol></div><div id="topicVersionRevision">Topic 14207 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Congenital Malformations and Developmental Anomalies of the Lung</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22409407" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Revisiting the histopathologic spectrum of congenital pulmonary developmental disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3448653" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The continuum of pulmonary developmental anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29328793" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Novel Molecular and Phenotypic Insights into Congenital Lung Malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31779656" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : New insights on congenital pulmonary airways malformations revealed by proteomic analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790364" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fetal lung lesions: management and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Congenital pulmonary airway malformation - a new name for and an expanded classification of congenital cystic adenomatoid malformation of the lung</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17558209" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fetal magnetic resonance imaging as a complement to fetal ultrasonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23525748" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Congenital lung lesions: prenatal MRI and postnatal findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12695920" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The value of fast MR imaging as an adjunct to ultrasound in prenatal diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9574750" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prenatal magnetic resonance imaging enhances fetal diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19099368" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Evidence to support that spontaneous preterm labor is adaptive in nature: neonatal RDS is more common in "indicated" than in "spontaneous" preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33252753" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Fetal ultrasound and magnetic resonance imaging: a primer on how to interpret prenatal lung lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10405718" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Congenital chest lesions: diagnosis and characterization with prenatal MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16731886" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A nomogram of fetal lung volumes estimated by 3-dimensional ultrasonography using the rotational technique (virtual organ computer-aided analysis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12821772" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fetal thoracic abnormalities: MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30008034" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The rare solid fetal lung lesion with T2-hypointense components: prenatal imaging findings with postnatal pathological correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16953677" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bronchial atresia is common to extralobar sequestration, intralobar sequestration, congenital cystic adenomatoid malformation, and lobar emphysema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15448330" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Congenital masses of the lung, cystic adenomatoid malformation versus congenital lobar emphysema: prenatal diagnosis and implications for postnatal treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9323669" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sonographic detection of bilateral fetal chest masses: report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18392629" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Congenital cystic lung disease: contemporary antenatal and postnatal management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19099310" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cystic adenomatoid malformation of the lung causing hydrops fetalis: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19099310" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cystic adenomatoid malformation of the lung causing hydrops fetalis: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22414029" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Congenital pulmonary airway malformation (CPAM) [congenital cystic adenomatoid malformation] associated with tracheoesophageal fistula and agensesis of the corpus callosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23350653" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Type 2 congenital pulmonary airway malformation and congenital nephrotic syndrome: report of a new association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24763516" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22244390" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Defining hydrops and indications for open fetal surgery for fetuses with lung masses and vascular tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16923695" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A cardiovascular profile score in the surveillance of fetal hydrops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11877643" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cystic adenomatoid malformation volume ratio predicts outcome in prenatally diagnosed cystic adenomatoid malformation of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26978067" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prenatal Diagnosis and Evaluation of Sonographic Predictors for Intervention and Adverse Outcome in Congenital Pulmonary Airway Malformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30199894" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fetal Congenital Pulmonary Airway Malformation: The Role of an Objective Measurement of Cardiomediastinal Shift.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17950681" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antenatal diagnosis and management of congenital cystic adenomatoid malformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19740261" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Congenital lung malformation: evaluation of prenatal and postnatal radiological findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prenatal imaging of bronchopulmonary malformations: Is there a role for late third trimester fetal MRI?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28631022" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Risk analysis and outcomes of bronchopulmonary sequestrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18634115" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cystic lung lesions - prenatal diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28189445" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Bilateral congenital lobar emphysema: staged management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20228324" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Congenital chest malformations: a multimodality approach with emphasis on fetal MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17101340" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Two cases of prenatally diagnosed congenital lobar emphysema caused by lobar bronchial atresia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19011806" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Perinatal management of common neonatal thoracic lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23341382" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Fetal umbilical vein deviation in congenital diaphragmatic hernia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28586146" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Locating the Level and Extent of Congenital High Airway Obstruction: Fluid in the Airway Tract as Reference Points.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27913050" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Congenital High Airway Obstruction Syndrome (CHAOS): A perinatal autopsy case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18634114" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : In utero therapy for fetal thoracic abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20620300" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Is congenital cystic adenomatoid malformation a premalignant lesion for pleuropulmonary blastoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17392009" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : [Pleuropulmonary blastoma: a case of early neonatal diagnosis through antenatal scan screening].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21107081" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Fetal lung interstitial tumor (FLIT): A proposed newly recognized lung tumor of infancy to be differentiated from cystic pleuropulmonary blastoma and other developmental pulmonary lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19540178" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Open fetal surgery for life-threatening fetal anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28589256" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Treatment of congenital pulmonary airway malformations: a systematic review from the APSA outcomes and evidence based practice committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28584070" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The natural history of prenatally diagnosed congenital cystic lung lesions: long-term follow-up of 119 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30715996" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Neoplasm Risk Among Individuals With a Pathogenic Germline Variant in DICER1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28405541" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : It's Rare So Be Aware: Pleuropulmonary Blastoma Mimicking Congenital Pulmonary Airway Malformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31256075" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Fetal lung interstitial tumor: Prenatal presentation of a rare fetal malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17270558" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Large fetal congenital cystic adenomatoid malformations: growth trends and patient survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17270561" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Ex utero intrapartum treatment with placement on extracorporeal membrane oxygenation for fetal thoracic masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18956429" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prenatal diagnosis and outcome of echogenic fetal lung lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25805010" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Vanishing fetal lung malformations: Prenatal sonographic characteristics and postnatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32622160" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prenatal Imaging to Predict Need for Urgent Perinatal Surgery in Congenital Lung Lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24888822" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fetal MRI lung volumes are predictive of perinatal outcomes in fetuses with congenital lung masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21519839" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Prospective study of antenatally diagnosed congenital cystic adenomatoid malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27458568" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pulmonary Malformations: Predictors of Neonatal Respiratory Distress and Early Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31593968" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The Utility of the Congenital Pulmonary Airway Malformation-Volume Ratio in the Assessment of Fetal Echogenic Lung Lesions: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23159697" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Fetal lung lesions: can we start to breathe easier?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31566736" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Congenital pulmonary airway malformation associated with mosaic Klinefelter syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27070354" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Prenatal and Postnatal Management of Congenital Pulmonary Airway Malformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14632303" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Expression of Hoxb-5 during human lung development and in congenital lung malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30740464" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cancer gene mutations in congenital pulmonary airway malformation patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31416986" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Whole exome sequencing to uncover genetic variants underlying congenital cystic adenomatoid malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34980466" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Neonatal congenital pulmonary airway malformation associated with mucinous adenocarcinoma and KRAS mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34211152" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12418767" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Fetal therapy: state of the art.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19683972" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Ex-utero intrapartum therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15991193" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The ex utero intrapartum therapy procedure for high-risk fetal lung lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19911412" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Hyperechoic congenital lung lesions in a non-selected population: from prenatal detection till perinatal management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21618254" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Prenatal interventions for fetal lung lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20105595" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Prenatal steroids for microcystic congenital cystic adenomatoid malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17001747" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : In-utero pulmonary drainage in the management of primary hydrothorax and congenital cystic lung lesion: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19159718" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : High-risk fetal congenital pulmonary airway malformations have a variable response to steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17556826" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Effect of maternal betamethasone administration on prenatal congenital cystic adenomatoid malformation growth and fetal survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22244389" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Microcystic congenital pulmonary airway malformation with hydrops fetalis: steroids vs open fetal resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25840053" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Favorable outcomes in high-risk congenital pulmonary airway malformations treated with multiple courses of maternal betamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26526208" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effect of single and multiple courses of maternal betamethasone on prenatal congenital lung lesion growth and fetal survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19559325" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Management of fetal lung lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32420654" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Comparison of the Prognostic Factors of Fetuses With Congenital Pulmonary Airway Malformations According to Type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25638624" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Thoracoamniotic shunts for the management of fetal lung lesions and pleural effusions: a single-institution review and predictors of survival in 75 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27489957" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Thoracoamniotic Shunts in Macrocystic Lung Lesions: Case Series and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36379747" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The long-term outcome following thoraco-amniotic shunting for congenital lung malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27469386" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Refractory tension pneumothorax as a result of an internally displaced thoracoamniotic shunt in an infant with a congenital pulmonary airway malformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30885769" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Subsequent pregnancy outcomes after open maternal-fetal surgery for myelomeningocele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11111218" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Percutaneous laser ablation of fetal congenital cystic adenomatoid malformation: too little, too late?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Intrauterine laser ablation of a fetal cystic adenomatoid malformation with hydrops: the application of minimally invasive surgical techniques to fetal surgery</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912498" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Laser ablation of foetal microcystic lung lesion: successful outcome and rationale for its use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22990987" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Percutaneous laser ablation under ultrasound guidance for fetal hyperechogenic microcystic lung lesions with hydrops: a single center cohort and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35490675" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Innovative Fetal Therapy for a Giant Congenital Pulmonary Airway Malformation with Hydrops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753764" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Percutaneous fetal sclerotherapy for congenital cystic adenomatoid malformation of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29665020" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Types II and III congenital pulmonary airway malformation with hydrops treated in utero with percutaneous sclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36670618" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Lifesaving Treatments for the Tiniest Patients-A Narrative Description of Old and New Minimally Invasive Approaches in the Arena of Fetal Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33214447" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Fetal Risk Stratification and Outcomes in Children with Prenatally Diagnosed Lung Malformations: Results from a Multi-Institutional Research Collaborative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11090372" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Congenital cystic adenomatoid malformation: impact of prenatal diagnosis and changing strategies in the treatment of the asymptomatic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29274787" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Expert surgical consensus for prenatal counseling using the Delphi method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35065806" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Delivery planning for congenital lung malformations: A CVR based perinatal care algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32151401" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : EXIT (ex utero intrapartum treatment) surgery for the management of fetal airway obstruction: A systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31093996" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Obstetric outcomes of ex-utero intrapartum treatment (EXIT).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
